U.S. market Closed. Opens in 11 hours 53 minutes

KPRX | Kiora Pharmaceuticals, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for KPRX we got that it has weak fundamentals where Valuation is considered to be fairly valued, Profitability is poor, Growth is bad and Health is weak.

Valuation (55%)

Company Industry
P/E Ratio (TTM) 4.44 -16.22
PEG Ratio (TTM) -0.18 -1.41
P/S Ratio (TTM) 0.62 48.82
P/B Ratio (TTM) 0.43 21.13
P/FCF Ratio (TTM) 2.14 9.38
Price to 5YR AVG Earnings Ratio -0.06 -0.21
Price to 5YR AVG FCF Ratio -1.09 -7.10

Profitability (45%)

Company Industry
ROA (TTM) 7.84% -3.10%
ROE (TTM) 15.57% 24.21%
Net Profit Margin (TTM) 19.63% -1,069.78%
ROIC 5YR AVG -265.72% 16.50%

Growth (50%)

4QTR AVG 3YR AVG 5YR AVG
EPS 34.76% 25.24% 24.61%
Revenue 1,359.12% -45.67% -27.40%
Net Income 129.16% -27.42% -11.45%
Cash Flow 104.00% -4.58% -0.23%

Health (49%)

Company Industry
Current Ratio (TTM) 19.22 5.75
Quick Ratio (TTM) 19.22 5.47
D/E Ratio (TTM) 0.00 -15.13
Interest Coverage (TTM) 77.69 3.59
Piotroski F-Score 4 5
Altman Z-Score N/A 13.47
LTL to 5YR AVG FCF -0.01 0.20
Shares Outstanding Growth 5YR AVG 73.21% 118.86%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙